Investigational drug · Phase 2
TVAX-008
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Chronic Hepatitis B, HBV Infection, Chronic Hepatitis B Virus.
Phase 2Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
6
Any phase or sponsor naming "TVAX-008"
First trial start
2023
Jun 1, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TVAX-008", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Hepatitis B
- HBV Infection
- Chronic Hepatitis B Virus
Approved drugs for the same conditions: Hepatitis B · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "TVAX-008" as an intervention, largest first.
- Clinical Trial to Evaluate the Efficacy and Safety of TVAX-008 Injection in the Treatment of Chronic Hepatitis BPivotal-lookingNot yet recruiting
Grand Theravac Life Sciences (Nanjing) Co., Ltd.Industry
NCT07282249 · 630 participants (planned) · Start Dec 31, 2025 · Primary completion Apr 30, 2027
Drug: TVAV-008; PegIFNα2b and 1 more · For: Chronic hepatitisB
- A Study of Sequential Therapy With AHB-137 Injection Followed by TVAX-008 Injection in Participants Living With Chronic Hepatitis B (CHB)Pivotal-lookingNot yet recruiting
Grand Theravac Life Sciences (Hangzhou) Co., Ltd.Industry
NCT07897448 · 105 participants (planned) · Start Oct 31, 2026 · Primary completion Sep 22, 2028
Drug: AHB-137; TVAX-008 and 2 more · For: Chronic Hepatitis B
- A Study of Sequential Therapy With AHB-137 Injection Followed by TVAX-008 Injection in Participants Living With Chronic Hepatitis B (CHB)Pivotal-lookingNot yet recruiting
Ausper Biopharma Co., Ltd.Industry
NCT07876856 · 105 participants (planned) · Start Oct 31, 2026 · Primary completion Sep 22, 2028
Drug: AHB-137; Placebo and 1 more · For: Chronic Hepatitis B
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of TVAX-008 Injection in Treated Patients With Chronic Hepatitis BActive, not recruiting
Grand Theravac Life Sciences (Nanjing) Co., Ltd.Industry
NCT07190742 · 80 participants (planned) · Start Jun 1, 2023 · Primary completion Oct 17, 2024
Drug: TVAX-008; Placebo · For: Chronic Hepatitis B Virus
Sites: Beijing, China
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of TVAX-008 Injection in Chronic Hepatitis B PatientsActive, not recruiting
Grand Theravac Life Sciences (Nanjing) Co., Ltd.Industry
NCT07179653 · 48 participants (planned) · Start Jan 22, 2025 · Primary completion Dec 2025
Drug: TVAX-008; Placebo · For: HBV Infection
Sites: Guangzhou, China
- Study to Evaluate Immunogenicity and Safety of TVAX-008 Injection in Non/Treated Chronic Hepatitis B Patients With HBsAg≤20IU/ml or HBsAg Negative Without Serological ConversionActive, not recruiting
Grand Theravac Life Sciences (Nanjing) Co., Ltd.Industry
NCT07204236 · 20 participants · Start Jan 18, 2024 · Primary completion Mar 1, 2025
Drug: TVAX-008 · For: Chronic Hepatitis B
Sites: Jinan, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Chronic Hepatitis B
- GST-HG141Phase 33 trials
Fujian Akeylink Biotechnology Co., Ltd. · Chronic Hepatitis b, Chronic Hepatitis B
- TAFPhase 33 trials
Gilead Sciences · HIV-1-infection, Chronic Hepatitis B
- TQA3605Phase 33 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chronic Hepatitis b, Chronic Hepatitis B, HBV Infection With LLV
- HRS-5635Phase 32 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Chronic Hepatitis B, Nucleos(t)Ide Analogue-suppressed HBeAg-negative Patients With Chronic Hepatitis B
- Peg-IFN-αpegylated interferonPhase 26 trials
Brii Biosciences Limited · Chronic Hepatitis B, Chronic Hepatitis B Virus (HBV) Infection, Hepatitis B, Chronic
- HT-101Phase 23 trials
Suzhou HepaThera Biotech Co., Ltd. · Chronic Hepatitis B, Chronic Hepatitis B Virus Infection
- HT-102Phase 23 trials
Suzhou HepaThera Biotech Co., Ltd. · Chronic Hepatitis B, Chronic Hepatitis B Virus Infection
- NAsNucleoside analogs, acidPhase 23 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chronic Hepatitis B, HBV Infection With LLV
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.